Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 2/20 | 0.99 |
| ▸ | PPP2CA | P67775 | 2/20 | 0.99 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.99 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.99 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.99 |
| ▸ | NPY4R | P50391 | 1/20 | 0.99 |
| ▸ | PPP2R5A | Q15172 | 1/20 | 0.99 |
| ▸ | MAPT | P10636 | 1/20 | 0.99 |
| ▸ | PPP6C | O00743 | 1/20 | 0.99 |
| ▸ | PPP5C | P53041 | 1/20 | 0.99 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Okadaic Acid SCHEMBL22024950 | 0.99 | PPM1B (1.00) | PPM1BPPP2CAPTPN1PPP1CCTFPI2 | |
| Okadaic Acid SCHEMBL21408784 | 0.99 | PPM1B (1.00) | PPM1BPPP2CAPTPN1PPP1CCTFPI2 | |
| Okadaic Acid SCHEMBL17899362 | 0.99 | PPM1B (1.00) | PPM1BPPP2CAPTPN1PPP1CCTFPI2 | |
| Okadaic Acid SCHEMBL23350437 | 0.99 | PPM1B (1.00) | PPM1BPPP2CAPTPN1PPP1CCTFPI2 | |
| Okadaic Acid SCHEMBL2386832 | 0.99 | PPM1B (1.00) | PPM1BPPP2CAPTPN1PPP1CCTFPI2 | |
| Okadaic Acid SCHEMBL24418495 | 0.99 | PPM1B (1.00) | PPM1BPPP2CAPTPN1PPP1CCTFPI2 | |
| Okadaic Acid SCHEMBL131485 | 0.99 | PPM1B (1.00) | PPM1BPPP2CAPTPN1PPP1CCTFPI2 | |
| Okadaic Acid SCHEMBL545397 | 0.99 | PPM1B (0.99) | PPM1BPPP2CAPTPN1PPP1CCTFPI2 | |
| Okadaic Acid SCHEMBL4446706 | 0.99 | PPM1B (0.99) | PPM1BPPP2CAPTPN1PPP1CCTFPI2 | |
| Okadaic Acid SCHEMBL29369982 | 0.99 | PPM1B (0.99) | PPM1BPPP2CAPTPN1PPP1CCTFPI2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118078980-A | Tolerogenic synthetic nanocarriers | 西莱克塔生物科技公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118078979-A | Tolerogenic synthetic nanocarriers for reducing immune responses to therapeutic proteins | 西莱克塔生物科技公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20240156955-A1 | TOLEROGENIC SYNTHETIC NANOCARRIERS | SELECTA BIOSCIENCES, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| US-20240148841-A1 | COMPOSITIONS AND METHODS RELATED TO IMMUNOGLOBULIN PROTEASES AND FUSIONS THEREOF | CARTESIAN THERAPEUTICS, INC. | 2024-05-09 | — | — | US | disclosed |
| EP-2701737-B1 | TOLEROGENIC SYNTHETIC NANOCARRIERS FOR ALLERGY THERAPY | SELECTA BIOSCIENCES INC (US) | 2024-03-27 | — | — | EP | disclosed |
| WO-2024036324-A1 | COMPOSITIONS AND METHODS RELATED TO IMMUNOGLOBULIN PROTEASES AND FUSIONS THEREOF | SELECTA BIOSCIENCES, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| EP-4319747-A1 | SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT IN COMBINATION WITH HIGH AFFINITY IL-2 RECEPTOR AGONISTS TO ENHANCE IMMUNE TOLERANCE | Selecta Biosciences, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-20240024517-A1 | VIRAL VECTOR DOSING PROTOCOLS | SELECTA BIOSCIENCES INC (US) | 2024-01-25 | — | — | US | disclosed |
| CN-117298266-A | Tolerogenic synthetic nanocarriers | 西莱克塔生物科技公司 | 2023-12-29 | — | — | CN | disclosed |
| CN-117320717-A | Synthetic nanocarriers comprising immunosuppressants in combination with high affinity IL-2 receptor agonists to enhance immune tolerance | 西莱克塔生物科技公司 | 2023-12-29 | — | — | CN | disclosed |
| WO-2012149255-A2 | TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE IMMUNE RESPONSES TO THERAPEUTIC PROTEINS | SELECTA BIOSCIENCES, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012149265-A2 | TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE CYTOTOXIC T LYMPHOCYTE RESPONSES | SELECTA BIOSCIENCES, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| US-8110551-B2 | Cytolethal distending toxin and use thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-02-07 | — | — | US | disclosed |
| US-20090202592-A1 | CYTOLETHAL DISTENDING TOXIN, INHIBITION AND USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-13 | — | — | US | disclosed |
| US-7452977-B2 | Antibody to a kinase capable of site-specific phosphorylation of IκBα | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-6787346-B2 | ENZYMATIC POLYPETIDE FOR USE IN THE TREATMENT OF INFLAMMATION, VIRAL, INFECTION, CANCER, SEPSIS, PSORIASIS AND RESTENOSIS | MILLENNIUM PHARMACEUTICALS, INC. | 2004-09-07 | — | — | US | disclosed |
| US-20040161814-A1 | Kinase Capable of site-specific phosphorylation of IkappaBalpha | MILLENNIUM PHARMACEUTICALS, INC. | 2004-08-19 | — | — | US | disclosed |
| US-20020168740-A1 | KINASE CAPABLE OF SITE-SPECIFIC PHOSPHORYLATION OF IKBA | MILLENNIUM PHARMACEUTICALS, INC. | 2002-11-14 | — | — | US | disclosed |
| US-20020151022-A1 | Kinase capable of site-specific phosphorylation of IkappaBalpha | MILLENNIUM PHARMACEUTICALS, INC. | 2002-10-17 | — | — | US | disclosed |
| US-6107073-A | UBIQUITIN DEPENDENT ENZYME WHICH IS PART OF A MULTISUBUNIT COMPLEX OF 700 KILODALTONS AND WHICH PHOSPHORYLATES I-KAPPA-B-ALPHA AT SERINES 32 AND 36; FOR SCREENING ENYZME INHIBITORS; ANTICARCINOGENIC/ANTIINFLAMMATORY AGENTS | LEUKOSITE, INC. | 2000-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024517-A1 | VIRAL VECTOR DOSING PROTOCOLS | HAVCR2, CD4, FCGR3B | PPM1B 1701/4885PPP2CA 3280/4885PTPN1 564/4885 |
| US-20240148841-A1 | COMPOSITIONS AND METHODS RELATED TO IMMUNOGLOBULIN PROTEASES AND FUSIONS THEREOF | IGSF11, RPS27A, VSIG8 | PPM1B 2347/4885PPP2CA 2304/4885PTPN1 1489/4885 |
| US-20240156955-A1 | TOLEROGENIC SYNTHETIC NANOCARRIERS | CD47, ICOS, MICA | PPM1B 704/4885PPP2CA 1083/4885PTPN1 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.